CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
CatalYm's visugromab lifted bladder cancer complete responses to 33% versus 8% with nivolumab alone. Can larger trials establish lasting benefit?
